DelveInsight Blog

Map the latest in Pharmaceutical, Healthcare, Medical Devices and Biotech Space with DelveInsight’s panoramic market analysis while the Pharma Industry continues to rapidly evolve with several approvals,failures, acquisitions, and partnerships teeing up the domain.

Pfizer’s DMD Gene Therapy: Main Game to Unexpected Failure. How Will Sarepta Benefit?

Duchenne muscular dystrophy (DMD) is a severe genetic disorder primarily affecting young boys between the ages of two and three. As per Delveinsight’s estimates, there were approximately 16K DMD patients in 2023 in the United States, with ˜75% of the patients below the age of 15. This condition leads to progressive muscle degeneration, initially presenting as muscle weakness and difficulties with movement. DMD is caused by mutations in the gene responsible for producing dystrophin, a crucial protein for muscle stability and function.  Estimated Patient Burden of DMD (2023) USA ˜16,000…

Takeda Showcase Phase III Results for Soticlestat; Imfinzi and Chemotherapy Combination Gains US Approval; Nipocalimab Shows Notable Efficacy in Phase II Study; Bristol Myers Squibb’s Augtyro FDA Approval; AstraZeneca’s Farxiga FDA Approval

Takeda Reveals Phase III Results for Soticlestat (TAK-935) in Dravet and Lennox-Gastaut Syndromes Takeda revealed topline results from its SKYLINE and SKYWAY studies. SKYLINE (TAK-935-3001) was a multicenter, randomized, double-blind Phase III trial assessing soticlestat (TAK-935) plus standard care against placebo plus standard care in patients with refractory Dravet syndrome. Soticlestat narrowly missed the primary endpoint of reducing convulsive seizure frequency from baseline compared to placebo (p-value = 0.06). However, in the six key secondary endpoints, soticlestat demonstrated clinically meaningful and nominally significant outcomes in the responder rate, caregiver and…

WINREVAIR Approval for Pulmonary Arterial Hypertension Treatment: Is It A Game-Changer for Merck?

Merck’s investment of $11.5 billion in acquiring Acceleron Pharma is expected to yield significant returns with the FDA’s approval of WINREVAIR (sotatercept), a pivotal component of the acquisition, for the treatment of pulmonary arterial hypertension. An estimated prevalence of pulmonary hypertension at the population level is approximately 1% to 3%. The total prevalent cases of PAH in the 7MM were found to be approximately 88K cases in 2022, which are expected to increase by 2034 at a CAGR of 0.4% during the study period (2020─2034). It is observed females are…

Moderna’s Phase III Trials for Dual Influenza and COVID-19 Vaccine; Almirall’...

Moderna Reports Successful Phase III Trials for Dual Influenza and COVID-19 Vaccine Moderna, Inc. has…

Find out more
The Dynamic Landscape of Myelofibrosis Treatment: A 2024 Perspective

Myelofibrosis is a rare disease with a high unmet need, with no disease-modifying treatments. Before…

Find out more
Dry AMD Treatment- An Underserved Market With Billion-Dollar Potential

Wet AMD, comprising around 10% of the total AMD population, is primarily the target of…

Find out more
Stryker’s LIFEPAK 35 Monitor/Defibrillator; Qiagen’s QIAstat-Dx Respiratory P...

Stryker Released LIFEPAK 35 Monitor/Defibrillator  On June 04, 2024, Stryker, a global leader in medical…

Find out more
Wireless Brain Sensors: Revolutionizing Neuroscience and Healthcare

The advancement of technology has ushered in an era where the fusion of biology and…

Find out more
Moderna’s mRESVIA(R) FDA Approval; Novartis Scemblix® Phase III Data; K...

FDA Greenlights Moderna's RSV Vaccine mRESVIA(R) Moderna, Inc. has announced that the FDA has approved…

Find out more
Artificial Intelligence (AI) in Mental Health
From Lab to Lifesaver: Advancing Artificial Blood Vessels for Healthier Tomorrows

Artificial blood vessels represent a critical frontier in medical research, offering significant promise for treating cardiovascular diseases and enhancing surgical outcomes. Future directions in this field are focused on developing materials that can closely mimic the natural properties of human blood vessels.

Find More
atopic-dermatitis-treatment-pipeline
Atopic Dermatitis Treatment: Rich Portfolio of Therapeutic Options Shaping the Future

Currently, a variety of candidate drugs for the treatment of atopic dermatitis are being tested in various clinical trials, with some showing positive results. Any drug approved with increased safety and efficacy is expected to cause significant changes in the overall atopic dermatitis market.

Find More
gsk-and-iteos-collaboration-for-belrestotug
GSK and iTeos Alliance Boosts Belrestotug Prospects in TIGIT Space

One of the most notable advancements in the anti-TIGIT landscape was the collaboration between GlaxoSmithKline and iTeos Therapeutics, around the time of peak TIGIT mania in 2021, culminating in a USD 625 million deal for the anti-TIGIT monoclonal antibody Belrestotug (EOS-448)

Find More
rise-of-sleep-tech-devices
The Rise of Sleep Tech Devices: Unlocking Better Sleep

As per the latest assessment by DelveInsight, the global sleep tech devices market was valued at ~USD 17 billion in 2023, growing at a CAGR of 17.31% during the forecast period from 2024 to 2030 to reach ~USD 44 billion by 2030.

Find More
Launch Landscape Analysis
Launch Landscape Analysis

A mid pharma client based in Germany, involved in late-stage development of a therapy for PID, with effective marketing and commercialisation presence in Europe, wanted to assess the launch readiness of competitors involved in the same arena for strategic positioning of their product. They wished to identify and evaluate the launch timelines, geographies of launch, First Launch company, commercial readiness, and salesforce of competitors.

A mid pharma client based in Germany, involved in late-stage development of a therapy for PID, with effective marketing and commercialisation presence in Europe, wanted to assess the launch readiness of competitors involved in the same arena for strategic positioning of their product. They wished to identify and evaluate the launch timelines, geographies of launch, First Launch company, commercial readiness, and salesforce of competitors.

Find More
Product Assessment
Product Assessment

A large pharma client was working to develop their cyclophosphamide API and FD and was interested to assess competitive products in the same domain and area to provide benchmarking of their asset in comparison to their competitors The client requested periodic reports (Quarterly) on the developmental milestones of competitor companies, thorough assessment of the competitor products through Secondary and Primary CI inputs.

A large pharma client was working to develop their cyclophosphamide API and FD and was interested to assess competitive products in the same domain and area to provide benchmarking of their asset in comparison to their competitors The client requested periodic reports (Quarterly) on the developmental milestones of competitor companies, thorough assessment of the competitor products through Secondary and Primary CI inputs.

Find More
Asset Prioritization
Asset Prioritization

A mid-sized pharma client was working to develop their asset portfolio and was interested in assessing best possible asset for atrial fibrillation for future development and licensing needs. The client requested evidence-based priorities in assets and products for Phase II development in atrial fibrillation, through potential licensing collaborations. Also, the client wanted to prioritise research efforts to determine the best possible asset to leverage their research portfolio.

A mid-sized pharma client was working to develop their asset portfolio and was interested in assessing best possible asset for atrial fibrillation for future development and licensing needs. The client requested evidence-based priorities in assets and products for Phase II development in atrial fibrillation, through potential licensing collaborations. Also, the client wanted to prioritise research efforts to determine the best possible asset to leverage their research portfolio.

Find More
Out Licensing Opportunity
Out-Licensing Opportunity

A small pharmaceutical client based at Sweden, Europe with capabilities around a neonatal mesenchymal cells involved DelveInsight to identify a licensing partner for their stem cells product, from across the globe. They wished to identify a potential list of companies, to become a fit for their neonatal high quality MSCs and can prove to be a good business partner as a licensee for their proprietary “API” of the stem cell therapy domain.

A small pharmaceutical client based at Sweden, Europe with capabilities around a neonatal mesenchymal cells involved DelveInsight to identify a licensing partner for their stem cells product, from across the globe. They wished to identify a potential list of companies, to become a fit for their neonatal high quality MSCs and can prove to be a good business partner as a licensee for their proprietary “API” of the stem cell therapy domain.

Find More
In Licensing Opportunity
In-Licensing Opportunity

A large client based in the USA, involved in drug delivery devices, with effective marketing and commercialisation presence across the globe, wanted to in-license potential dMTS based drug delivery asset from companies involved in microneedle technology research for delivering therapeutic products. They wished to identify and assess the technological competencies, clinical capabilities and commercial readiness of potential companies with a novel and non-invasive way of delivering drugs, which can include a variety of drugs/vaccines in their patch and successfully develop the product for commercial purposes, were of client’s interest.

A large client based in the USA, involved in drug delivery devices, with effective marketing and commercialisation presence across the globe, wanted to in-license potential dMTS based drug delivery asset from companies involved in microneedle technology research for delivering therapeutic products. They wished to identify and assess the technological competencies, clinical capabilities and commercial readiness of potential companies with a novel and non-invasive way of delivering drugs, which can include a variety of drugs/vaccines in their patch and successfully develop the product for commercial purposes, were of client’s interest.

Find More
Go To Market Strategy
Go-To-Market Strategy

A medium pharmaceutical client based in the United States with biosimilar commercial capabilities involved DelveInsight to identify commercial processes and strategies to launch their biosimilar in Europe through Competitive Assessment of their EU based competitors in the same area of interest. They wished to identify manufacturing sites, logistic operations, distribution network, salesforce assessment and their sales targets.

A medium pharmaceutical client based in the United States with biosimilar commercial capabilities involved DelveInsight to identify commercial processes and strategies to launch their biosimilar in Europe through Competitive Assessment of their EU based competitors in the same area of interest. They wished to identify manufacturing sites, logistic operations, distribution network, salesforce assessment and their sales targets.

Find More

See How We Do It

Our Consulting Services
Consulting Services

Optimized, competent, and dependable solutions to tackle fast-paced pharma market challenges.

Our Pharma Market Reports
Pharma Market Reports

Credible, data-driven, & analytical pharma & biotech market research & analysis for a holistic understanding.

Our MedTech Insights
MedTech Insights

Clinical solutions for vastly expanding diagnostics, digital therapeutics, & the MedTech industry.